Cancers & treatments·Regimen libraryFirst line

Venetoclax + obinutuzumab (fixed duration)

Checked 2026-09-09

Untreated CLL, all fitness levels

One cycle

every 28 days × 12 · about 48 weeks in total

28-day cycle × 12 (venetoclax cycles 1 day 22 to end of cycle 12; obinutuzumab cycles 1-6) (about 48 weeks)IntravenousOral Daily oral course

Components

Drug	Dose	Route	Days	Note
Obinutuzumab Monoclonal antibody (anti-CD20, glycoengineered type II)	100 mg day 1, 900 mg day 2, 1,000 mg days 8 and 15 (cycle 1); 1,000 mg day 1 cycles 2-6	IV	D1, 2, 8, 15
Venetoclax Small-molecule BCL-2 inhibitor	20 → 50 → 100 → 200 → 400 mg weekly ramp-up from cycle 1 day 22, then 400 mg daily	Oral	D22-28

Cycles

12 (venetoclax cycles 1 day 22 to end of cycle 12; obinutuzumab cycles 1-6)

28-day cycle

Emetogenicity

Minimal (<10%)

G-CSF

Not routine

Notes

Tumour lysis risk stratified by lymph node size and lymphocyte count; hospital ramp-up for high risk.
Strong CYP3A inhibitors are contraindicated during ramp-up.

Used in

Chronic lymphocytic leukaemia

Trials

CLL14 CLL13 / GAIA

Products

ObinutuzumabVenetoclax

Source

CLL14, NEJM 2019

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers

Bendamustine + rituximab (BR)

Indolent lymphoma and mantle cell lymphoma first line; fit CLL without del(17p) where targeted agents are unavailable

every 28 days × 6

Chlorambucil-prednisone (C+P)

Historic first-line treatment for symptomatic, advanced chronic lymphocytic leukaemia, given every two weeks and continued to maximal response; superseded by fludarabine combinations, chlorambucil-obinutuzumab and the BTK and BCL2 inhibitors

every 14 days

All regimens VRd →